Oocyte production and ovarian steroid concentrations of immature rats in response to some commercial gonadotrophin preparations.
Henderson. K M KM; Weaver. A A; Wards. R L RL; Ball. K K; Lun. S S; Mullin. C C; McNatty. K P KP
Key Findings
- Ovagen (very high FSH:LH ratio) produced high numbers of oocytes when given by continuous infusion
- Continuous infusion was more effective than single injections for most gonadotrophin preparations
- A modest LH supplement increased oocyte yield and improved the estradiol‑to‑androgen balance, but excess LH reduced both
Practical Outcomes
- If you’re experimenting with ovarian stimulation, consider a high‑FSH product like Ovagen delivered via a steady‑rate method (e.g., pump) rather than one‑off injections. Adding a low dose of LH can enhance outcomes, but keep LH low to avoid dropping estrogen levels and egg counts.
Summary
In rats, the FSH‑heavy drug Ovagen boosted egg production almost as well as other high‑FSH products, but only when given continuously rather than as a single shot. Adding a little extra LH helped even more, while too much LH hurt the results.
Abstract
Four commercial gonadotrophin preparations, namely Folligon, F.S.H.-P., Folltropin and Ovagen, were examined for their effects on oocyte production and ovarian steroid concentrations in immature rats. The ratios of the FSH to LH concentrations of the preparations, determined by radioreceptor assays, were Folligon 5, F.S.H.-P. 18, Folltropin 49 and Ovagen 1090. Forty-eight hours after administering each gonadotrophin preparation to immature rats, ovulation was induced by injection of chorionic gonadotrophin. Twenty-four hours later, oocytes were recovered from the oviducts and counted. Oocytes were produced after injection of chorionic gonadotrophin following a single injection of Folligon (10-50 i.u.). However, no oocytes were produced in response to the other gonadotrophin preparations unless they were administered by continuous infusion (30-1000 micrograms day-1). When given by injection (Folligon) or infusion (others), the gonadotrophin preparations all promoted a dose-dependent increase in mean oocyte production, except at the highest doses when mean oocyte numbers either remained unchanged or declined significantly in the cases of Folligon and F.S.H.-P. The highest mean numbers of oocytes produced in response to Folltropin (48 +/- 9 oocytes, mean +/- s.e.m.) and Ovagen (47 +/- 7) were greater than those attained with Folligon (21 +/- 6) or F.S.H.-P. (31 +/- 5). Mean ovarian weights also increased in a dose-dependent fashion in response to each of the gonadotrophin preparations. Measurements of ovarian steroid concentrations 48 h after the onset of gonadotrophin treatment (i.e. immediately prior to ovulation induction with chorionic gonadotrophin) showed that the gonadotrophin preparations markedly influenced the ratios of ovarian oestradiol-17 beta and androgen (androstenedione plus testosterone) concentrations. At low doses the gonadotrophin preparations increased the ratio of oestradiol-17 beta to androgens, but at the highest doses, with the exception of Ovagen, the ratio was reduced relative to peak values. Co-infusion of ovine LH (NIADDK-oLH-25; 10-20 micrograms day-1) with Ovagen (250 micrograms day-1) or ovine FSH (10 micrograms day-1, NIADDK-oFSH-17), both low in LH content, increased the mean number of oocytes produced and also the ovarian oestradiol-17 beta:androgen concentration ratio. However, with 40 micrograms LH day-1, the oestradiol-17 beta:androgen ratio fell due to a continued increase in mean ovarian androgen concentrations and a decrease in mean ovarian oestradiol-17 beta concentration. The mean number of oocytes produced also fell significantly.(ABSTRACT TRUNCATED AT 400 WORDS)
Study Information
pubmed
1990
10.1071/rd9900671